Advanced Search
Contact | Corporate | Help

Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Sponsors:
  • Dana-Farber Cancer Institute
  • Brigham and Women's Hospital
  • Massachusetts General Hospital
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Esophageal Cancer
  • Stomach Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Bevacizumab
  • Drug: Docetaxel
  • Drug: Cisplatin
  • Drug: Irinotecan
Enrollment:
35

Additional information about NCT00394433.


SourceSolution © 2008-2012